Actively Recruiting
Randomized Study of SPN-812 Versus Placebo in 4- to 5-Year-Old Children With ADHD to Assess Efficacy and Safety
Led by Supernus Pharmaceuticals, Inc. · Updated on 2026-10-05
286
Participants Needed
54
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.
CONDITIONS
Brief Title
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Research Team
O
Olivia Elbaum
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here